替罗非班与低相对分子质量肝素钙在预防支架内血栓形成的对比研究

目的比较替罗非班与低相对分子质量肝素钙（LMWH）在预防支架血栓形成中的有效性与安全性。方法选取PCI治疗的患者430例随机分为替罗非班组（n=220）和LMWH组（n=210），两组患者均予以阿司匹林、氯吡格雷抗血小板等相同基础治疗，分别给予替罗非班和LMWH治疗48h；观察两组患者PCI术后支架血栓形成、心血管意外事件发生情况及该药物在使用过程中的安全性。结果替罗非班组亚急性支架内血栓形成及顽固性心肌缺血显著低于LMWH组（P〈0．05），两组均无严重出血并发症，出血事件发生率无明显差异。结论支架术后患者使用替罗非班能使冠脉内血栓形成明显减少，使主要心血管不良事件的发生明显降低。

A Comparative Study of Tirofiban and Low-molecular-weight Heparins Calcium in Prevention of Stent Thrombosis

Objective To compare the efficacy and safety of tirofiban and low molecular weight hepa- rins calcium （LMWH） in prevention of stent thrombosis. Methods A total of 430, patients accepted PCI were randomly divided into tirofiban group（ n = 220）and LMWH group（ n =210）. Both groups were used aspirin and clopidogrel, tirofiban group and LMWH group were given tirofiban or LMWH for 48 hours. The incidence of cardiovascular accidents, stent thrombosis and the security of using the drug after PCI were observed. Re- sults Subacute stent thrombosis and refractory myocardial ischemia of tirofiban group is significantly lower than LMWH group＇s. There is no serious hemorrhagic complications in both groups and bleeding event rates are not significantly different. Conclusion Using of tirofiban in patients can reduce the coronary thrombosis and major adverse cardias events （MACE）significantly after the PCI.